Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

331 ARTÍCULOS , VIENDO DEL 241 AL 255

Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer's Disease: A Review of the Literature

McClam TD, Marano CM, Rosenberg PB, Lyketsos CG.

Harv Rev Psychiatry. 2015 Sep-Oct;23(5):377-93. doi: 10.1097/HRP.0000000000000097.

Longitudinal Associations between Survival in Alzheimer's Disease and Cholinesterase Inhibitor Use, Progression, and Community-Based Services

Wattmo C, Londos E, Minthon L.

Dement Geriatr Cogn Disord. 2015;40(5-6):297-310. doi: 10.1159/000437050. Epub 2015 Sep 4.

Treatment Options in Alzheimer´s Disease: The GABA Story

Solas M, Puerta E, Ramirez MJ.

Curr Pharm Des. 2015;21(34):4960-71. doi: 10.2174/1381612821666150914121149.

Progresses in treating agitation: a major clinical challenge in Alzheimer's disease

Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Santamato A, Lozupone M, Prete C, Greco A, Pilotto A, Logroscino G.

Expert Opin Pharmacother. 2015;16(17):2581-8. doi: 10.1517/14656566.2015.1092520. Epub 2015 Sep 21.

Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis

Matsunaga S, Kishi T, Annas P, Basun H, Hampel H, Iwata N.

J Alzheimers Dis. 2015;48(2):403-10. doi: 10.3233/JAD-150437.

A case of donepezil-related torsades de pointes

Kitt J, Irons R, Al-Obaidi M, Missouris C.

BMJ Case Rep. 2015 Oct 5;2015:bcr2015211900. doi: 10.1136/bcr-2015-211900.

Protein structures in Alzheimer's disease: The basis for rationale therapeutic design

Montoliu-Gaya L, Villegas S.

Arch Biochem Biophys. 2015 Dec 15;588:1-14. doi: 10.1016/j.abb.2015.10.005. Epub 2015 Oct 22.

[Rethinking the organization for preventing abuse]

Bonnery AM.

Soins Gerontol. 2015 Nov-Dec;(116):1. doi: 10.1016/j.sger.2015.09.001.

Drug and Exercise Treatment of Alzheimer Disease and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Effects on Cognition in Randomized Controlled Trials

Ströhle A, Schmidt DK, Schultz F, Fricke N, Staden T, Hellweg R, Priller J, Rapp MA, Rieckmann N.

Am J Geriatr Psychiatry. 2015 Dec;23(12):1234-1249. doi: 10.1016/j.jagp.2015.07.007. Epub 2015 Jul 21.

[Vitamin E and Alzheimer's Disease]

Shinohara M, Yamada M.

Brain Nerve. 2015 Dec;67(12):1509-13. doi: 10.11477/mf.1416200330.

Early detection of cognitive disorders: Follow-up study

Cabrera AG, Peña MC, Abd Elaziz KM, Allam MF.

Can J Neurosci Nurs. 2015;37(2):42-6.

Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor

Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B, Seiger A, Blennow K, Karami A, Darreh-Shori T, Wiberg M, Simmons A, Wahlund LO, Wahlberg L, Eriksdotter M.

J Alzheimers Dis. 2015;43(3):1059-72. doi: 10.3233/JAD-141068.

Alzheimer's disease

Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL.

Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56.

The biomarker and therapeutic potential of miRNA in Alzheimer's disease

Bekris LM, Leverenz JB.

Neurodegener Dis Manag. 2015;5(1):61-74. doi: 10.2217/nmt.14.52.

What lessons can be learned from failed Alzheimer's disease trials?

Toyn J.

Expert Rev Clin Pharmacol. 2015 May;8(3):267-9. doi: 10.1586/17512433.2015.1034690. Epub 2015 Apr 10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias